- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 88,590 | 03.06.24 10:18:49 | -1,190 | -1,33% | 88,590 | 88,650 | 88,320 | 89,780 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 900,200 | 03.06.24 08:16:58 | +1,800 | +0,20% | 899,200 | 909,600 | 900,200 | 898,400 |
